Foster & Motley Inc. Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Foster & Motley Inc. decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,156 shares of the medical research company’s stock after selling 293 shares during the quarter. Foster & Motley Inc.’s holdings in Thermo Fisher Scientific were worth $2,091,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. VELA Investment Management LLC raised its position in Thermo Fisher Scientific by 138.3% in the 2nd quarter. VELA Investment Management LLC now owns 5,622 shares of the medical research company’s stock worth $2,279,000 after buying an additional 3,263 shares during the last quarter. Chevy Chase Trust Holdings LLC raised its position in Thermo Fisher Scientific by 12.2% in the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 272,082 shares of the medical research company’s stock worth $110,318,000 after buying an additional 29,510 shares during the last quarter. Easterly Investment Partners LLC purchased a new position in Thermo Fisher Scientific in the 2nd quarter worth about $2,618,000. Arista Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $1,167,000. Finally, Koa Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 3.5% during the 2nd quarter. Koa Wealth Management LLC now owns 4,144 shares of the medical research company’s stock valued at $1,680,000 after purchasing an additional 140 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.4%

Shares of NYSE:TMO opened at $539.05 on Friday. The stock has a 50 day moving average of $495.74 and a 200 day moving average of $449.13. The company has a market cap of $203.55 billion, a PE ratio of 31.18, a price-to-earnings-growth ratio of 2.93 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the company posted $5.37 EPS. The firm’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock valued at $14,182,963. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on TMO shares. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, October 12th. UBS Group boosted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Barclays boosted their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. JPMorgan Chase & Co. boosted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Finally, Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research note on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $589.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.